期刊文献+

Ki67、Her-2在Luminal型乳腺癌中表达的相关性研究 被引量:1

Correlation of Her-2 and Ki67 expression in the luminal breast cancer
在线阅读 下载PDF
导出
摘要 目的探讨Ki67与Her-2在Luminal型乳腺癌组织中的表达的相关性及与病理分级之间的关系。方法采用免疫组织化学法(IHC)检测221例甲醛固定的乳腺癌组织标本中Ki67和Her-2的表达强度以及组织病理学分级,用Spearman秩相关分析Ki67、Her-2的表达强度以及组织病理学分级的相关性。结果 Ki67与Her-2的表达强度呈中度正相关(r=0.605,P<0.01),Her-2的表达强度与组织病理学分级呈中度正相关(r=0.455,P<0.01),Ki67的表达强度与病理分级呈正相关(r=0.489,P<0.01)。结论在Luminal型乳腺癌组织中,Ki67、Her-2的表达强度、组织病理分级之间呈正相关,用IHC检测Ki67的表达及病理分级对Her-2阳性判断具有参考价值。 Objective To investigate the correlation among Ki67. Her-2 expression intensity and the pathological grade in the Luminal breast cancer tissue. Methods The Ki67, Her-2 expression intensity and histopathological grade were detected by immuno-histochemistry(IHC) in 221 cases of formalin-fixed breast cancer tissue specimens. The correlation of Ki67, Her-2 expression inten sity,and histopathologic grade were analyzed by the Spearman rank correlation. Results The expression intensity of Ki67 was mod- erate positive correlative with that of Her-2(r=0. 605 ,P〈0.01) ,the expression intensity of Her-2 showed a moderate positive cor-relative with histopathologic grade(r=0. 455, P%0.01). The expression intensity of Ki67 was positively correlative with the patho- logical grade(r=0. 489,P〈0.01). Conclusion The expression intensity of the Ki67, Her-2 and histopathological grade are posi-tively correlate in the Luminal breast cancer tissue. The judgment of Her-2 positive can refer to the Ki67 expression and pathological grade detected with IHC.
出处 《重庆医学》 CAS CSCD 北大核心 2013年第16期1820-1821,1823,共3页 Chongqing medicine
基金 韶关市科技计划项目(2012CX/K72)
关键词 乳腺肿瘤 KI67 HER-2 病理分级 相关性 breast neoplasms Ki6 7 Her-2 pathological grade correlation
  • 相关文献

参考文献13

  • 1Sorlie T, Perou CM, Tibshirani R, et al. Gene expression pauerns of breast carcinomas distinguish tumor subclas- ses with clinical implications [J ]. Proc Natl Acad Sci USA,2001,98(9) : 1086 -1087.
  • 2Carey I.A,Dees EC, Sawyer L, et al. The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res,2007, 13(8):2329-2334.
  • 3Banerjee S. Reis-Filho JS, Ashley S,et al. Basal-like hreast carcinomas: clinical outcome and response to chemothera- py[J].J Clin Patho1,2006 ,.59(7) :729-735.
  • 4Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [J].Cancer, 2007,109(1) :25-32.
  • 5Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes dealing with the diversity of breast cancer: high- lights of the St Callen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J].An- nals of Oncology,2011(22) :1736-1747.
  • 6Maecallum D, Pa H. The location of pKi67 in the outer dense fibriilary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle[J].J Pathol,2000,190(5):537-544.
  • 7J alave P, Kuopio T, Juntti Patine L, et al. Ki67 immuno- histochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index[J]. Histopatholog, 2006,48 (6) : 674-682.
  • 8Williams Daron J,Cynthia C, Mary D, et al. Proliferation (Ki-67 and Phosphohistone H3) and oncotype DX recur- rence score in estrogen receptor-positive breast cancer[J]. Applied Immunohistochemistry Molecular Mor- phology,2011,19(4) :431-436.
  • 9Singhai R,Patil VW, Patil AV. Status of HER-2/neu re- ceptors and Ki67 in breast cancer of Indian wome[J]. Int J App Basic Med Res,2011,15(1) :15-19.
  • 10Li X,Liu M,Zhang Y,et al. ER,PgR,HER 2,Ki-67,to- poisomerase IIa, and nm23-H1 proteins expression as pre-dictors of palhological complete response to neoadjuvant chemotherapy for locally advanced breast cancer[J]. Med ical Oncology,2011,28(1) :48-54.

二级参考文献12

共引文献15

同被引文献9

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部